Condition: Chronic Kidney Disease · Sponsor: University Hospital, Montpellier
To evaluate the relationships between bone mineral metabolism markers (osteoprotegerin, fibroblast growth factor 23) at inclusion and the occurence of cardiovascular events during a 7 year follow-up.
This description comes directly from the study's public registry record.
Jean-Paul CRISTOL, Prof · +33(0)4 67 33 83 15 · jp-cristol@chu-montpellier.fr
Marion Morena, PhD · +33(0)4 11 75 98 93 · m-morenacarrere@chu-montpellier.fr
Always discuss trial participation with your own doctor first.
| AIDER | Montpellier, France | Recruiting |
| CHU Montpellier, Cardiology department | Montpellier, France | Active Not Recruiting |
| CHU Montpellier, Endocrinology department | Montpellier, France | Recruiting |
| CHU Montpellier, Intensive care unit | Montpellier, France | Active Not Recruiting |
| CHU Montpellier, Internal medicine department | Montpellier, France | Active Not Recruiting |
| CHU Montpellier, Nephrology department | Montpellier, France | Recruiting |
| AIDER | Saint-Jean-de-Védas, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02808572